Astells Withdraws Darexaban Japanese NDA
This article was originally published in PharmAsia News
Astellas has withdrawn a new drug application for oral factor Xa inhibitor darexaban with the Ministry of Health, Labor and Welfare
You may also be interested in...
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.